Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for USP6-Driven Oncology and Bone Pathology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for USP6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | USP6 Recombinant Protein (Catalytic Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli / Insect cell expressed. |
View USP6 Products |
| Gene Delivery | USP6 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View USP6 Products |
| Benchmark Ab | Anti-USP6 Recombinant Antibody Recombinant positive control for western blot, IHC, and IP. |
View USP6 Products |
| Validator | USP6 siRNA Set For knockdown verification in functional assays. |
View USP6 Products |
| Related Target A | CDH11 Osteoblast cadherin; forms the CDH11-USP6 fusion gene driving Aneurysmal Bone Cysts (ABC). |
View CDH11 Products |
| Related Target B | USP7 Crucial deubiquitinating enzyme for selectivity counter-screening panels. |
View USP7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-throughput screening for DUB enzymatic activity | Highly active USP6 catalytic domain proteins available with >95% purity and verified enzymatic cleavage potential. |
| DUB family selectivity counter-screening | A comprehensive panel of homolog DUB proteins (USP7, USP14, USP10) strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies and sequence-verified positive controls included. |
| False Positives in small molecule screens | Validated siRNA sets included for cellular target knockdown and specificity checks. |
Live USP6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for USP6 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum deubiquitinating enzyme (DUB) inhibitors to highly selective small molecule inhibitors. USP6 (Ubiquitin Specific Peptidase 6, also known as Tre2) is an oncogene structurally characterized by a catalytic DUB domain. Its dysregulation—primarily via the CDH11-USP6 translocation—is the primary driver of Aneurysmal Bone Cysts (ABC) and nodular fasciitis. As first-generation DUB inhibitors reach preclinical and early clinical validation, the next wave of R&D is targeting highly selective, allosteric USP6 inhibitors to avoid systemic toxicity associated with pan-DUB inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Ubiquigent, Mission Therapeutics, Academic Consortia | Aneurysmal Bone Cyst (ABC), Nodular Fasciitis, Solid Tumors | Enzymatic Assay (Need highly active recombinant USP6 catalytic domain for Ub-AMC/Ub-Rho110 cleavage assays) |
| PROTAC / Degraders | Early-stage Biotech Startups | USP6-translocated Sarcomas, Bone Tumors | Ubiquitination/Degradation Validation (Need high-purity USP6 protein and stable cell lines) |
| Gene Therapy / RNAi | Academic Research Institutes | Local Bone Pathologies | Target Knockdown Validation (Need sequence-verified USP6 siRNA and Lentiviral delivery) |